Ozempic, GLP-1s, and Longevity: Can Microdosing Help You Live Longer?
Wellness & SelfcareHealthy LivingLongevity

Can Ozempic and Other GLP-1s Really Increase Your Longevity?

Can Ozempic and Other GLP-1s Really Increase Your Longevity?
Adobe Stock
By
Updated on January 13, 2026
by

It seems like everywhere we turn, someone’s talking about glucagon-like peptide-1 (GLP-1) receptor agonist medications — and for good reason. You more than likely already know the names: semaglutide (Ozempic, Wegovy) and the dual GIP/GLP-1 agonist tirzepatide (Mounjaro, Zepbound).

Initially created to treat type 2 diabetes,

 these drugs are approved by the U.S. Food and Drug Administration (FDA) for obesity, obstructive sleep apnea, heart health risk reduction, and metabolic dysfunction–associated steatohepatitis (MASH).

Some online clinics and medical spas are now advertising GLP-1s as longevity treatments, which begs the question, could GLP-1s help people live longer, healthier lives? The honest answer: We don’t know yet. Here’s what we do know about what the research says.

GLP-1s and Longevity: The Science

“If we’re asking if GLP-1s make you live longer, like more number of years, we have no data and no science to support that,” says Rekha Kumar, MD, an endocrinologist and obesity medicine expert at Iris Cantor Women's Health Center in New York City. “If the question is, could this class of medicine keep you healthier for longer within your lifespan, the answer is the science is moving in that direction to support that.”

Researchers are actively studying how GLP-1 drugs impact key biological processes — including chronic inflammation, cellular energy, heart health, and brain function — all of which are major factors that determine both how long you live, which is known as lifespan, and how healthy you are during those years, which is referred to as healthspan.

“In cellular studies, we see reduced chronic inflammation, improved mitochondrial function [cell energy], better vascular function [blood flow], reduced oxidative stress,” says Dr. Kumar. “All of these things are cellular evidence that GLP-1s can be helpful.”

According to Reshmi Srinath, MD, director of the Mount Sinai Weight and Metabolism Management Program in New York City, research is taking place to establish if GLP-1s may have even more impact on factors related to aging.

“Drug companies are currently investigating the role of GLP-1s in aging and immune function, and they’re being studied in autoimmune disease and neurological conditions,” she says.

Inflammation and Aging

One reason GLP-1s are linked to longevity is their effect on oxidative stress, which is an imbalance of harmful molecules called free radicals that damage cells and trigger chronic inflammation.

 Sometimes called “inflammaging,” chronic inflammation is a major factor in age-related decline.

“GLP-1s reduce inflammation in the body,” says Kumar. “That type of inflammation not only leads to cardiovascular disease, but also to cancers, neurodegenerative disease (Alzheimer’s disease and Parkinson’s), and arthritis.”

Heart and Organ Protection

Protecting the heart — the organ most associated with early death — is another area of scientific interest.

“The SELECT trial found that people taking GLP-1s had a lower risk of heart attack, stroke, and death, even when they didn’t lose much weight,” says Kumar. “This shows the benefits go beyond just weight or blood sugar.”

 Beyond the heart, GLP-1s may help protect the kidneys and liver from damage caused by metabolic disease, a group of conditions that include hypertension, and abdominal obesity.

Cancer and Metabolic Health

Researchers are also exploring GLP-1s for the prevention of obesity-related cancers, which make up nearly 40 percent of U.S. cancer diagnoses. There are 13 types of cancers that are linked to obesity, including breast, colon and rectal, liver, and pancreatic cancer.

“For patients who don’t need to lose weight or treat diabetes, there’s growing interest in using GLPs to prevent chronic conditions like cancer,” says Kumar. “The benefits appear to come from both direct effects and improvements in blood sugar and body fat.”

Cellular Aging

Cellular aging is the gradual decline in a cell’s ability to function properly. Research indicates that GLP-1s may improve the function of mitochondria — structures within cells that produce almost all the energy your body needs — and reduce cellular stress, says Kumar.

“It could be hypothesized or extrapolated that this would also have a benefit on cellular aging,” she says.

Brain Health and Neuroprotection

Science is suggesting that GLP-1s may have a protective effect on the brain, too. Early studies suggest semaglutide may lower Alzheimer’s disease risk in people with type 2 diabetes by reducing inflammation, improving blood sugar, and protecting brain cells. However, research in otherwise healthy adults is still limited, and GLP-1s are not yet approved for preventing dementia.

Kumar describes a patient with a strong family history of Alzheimer’s who asked to try a GLP-1 for dementia prevention. “She was very fit and optimized her lifestyle, diet, sleep, and stress management,” she says. “We tried it, but she didn’t tolerate it — she became nauseous and lost weight she didn’t need.”

In this case, the risk outweighed the potential benefits, raising the question of whether GLP-1s offer the same longevity advantages for people without a medical indication for their use.

Are GLP-1 Drugs Approved for Longevity?

Despite early buzz about possible benefits, GLP-1 medications are not FDA-approved for longevity or preventing age-related disease. Yet doctors can prescribe them off-label for patients.

Still, there are important considerations. Off-label use is rarely covered by insurance, which can lead to high out-of-pocket costs, and has pushed some people toward compounded GLP-1 products, which are medications made by a pharmacy to create customized doses. Unlike brand-name GLP-1s, these products are not FDA-approved, so safety, purity, and effectiveness may vary.

Kumar urges anyone thinking about GLP-1s for longevity or healthspan to sit down with their doctor, not fill out a quick form online.

“I don’t think patients always know what they’re asking when they say they want a GLP-1 for longevity,” he says. “Are they hoping to live longer? Reduce inflammation? I don't think any of these conversations can really move forward without talking about lifestyle risk factor modification.”

Microdosing GLP-1s

Many of the compounding pharmacies marketing GLP1s for longevity suggest microdosing, or taking very small doses of the medication. The idea is that tiny doses might provide benefits while lowering the risk of side effects, while potentially limiting the amount of weight loss for people who aren’t seriously overweight.

While microdosing is not officially recommended by drugmakers and lacks large-scale clinical trial evidence, Kumar says, “It does make sense. … If a smaller dose works for someone, if they feel better and their inflammation improves, then they don’t necessarily need a higher dose.”

Yet microdosing should only be done with medical guidance. “I work with patients individually to adjust medication doses based on their progress and weight loss and as they reach their goal,” says Dr. Srinath.

Are GLP-1 Drugs Safe for Everyone?

There haven’t been enough studies to make that determination yet. Long-term data is limited because these drugs are relatively new.

“These drugs have tremendous benefit, but more ongoing studies are needed outside of patients with diabetes, obesity, and metabolic disease before we can apply safely,” says Srinath.

Like any medication, GLP-1s can cause side effects, including acid reflux, constipation, fatigue, headaches, indigestion, mild nausea, and vomiting. These symptoms often lessen as your body adjusts or your dose is decreased. Some studies show side effects may be more pronounced in older adults, increasing the likelihood they’ll stop taking it.

People aged 65 and older may also be more susceptible to muscle mass loss, which is concerning since age naturally reduces bone and muscle strength, increasing the risk of falls and fractures.

Other, rarer side effects include gallstones, pancreatitis, and severe gastrointestinal issues such as bowel obstruction or gastroparesis, which is when stomach muscles are unable to move food properly into the digestive system.

GLP-1 medications can benefit many people, but they aren’t the right choice for everyone. Your doctor may advise against them if you:

  • Have a personal or family history of certain thyroid cancers, including medullary thyroid cancer (MTC) or multiple endocrine neoplasia type 2 (MEN2)
  • Are pregnant, breastfeeding, or planning a pregnancy
  • Have had pancreatitis
  • Have serious stomach or gastrointestinal problems
  • Have a history of an eating disorder or disordered eating
  • Drink a lot of alcohol
  • Are medically frail or have very low muscle mass
  • Aren’t able to make supportive lifestyle changes, like adjusting eating patterns or increasing activity

Kumar stresses the importance of working closely with your doctor to not only monitor risk factors and side effects but to make sure you are setting foundational health habits. “There’s no real benefit to adding a GLP-1 for longevity if you can still modify lifestyle risk factors. It’s going to be less effective,” she says. “Once someone has done all the right things for nutrition, fitness, sleep, stress management, and frailty prevention, then having a conversation about adding a pharmacologic option for longevity or optimization becomes appropriate.”

The Takeaway

  • GLP-1 medications, like semaglutide and tirzepatide, were originally developed for diabetes, but researchers are now exploring if they may extend lifespan and help people maintain good health for a longer period of time.
  • Early evidence suggests GLP-1s may reduce chronic inflammation and improve cellular function, supporting heart, liver, kidney, and brain health, and potentially lowering risk for obesity-related cancers. However, there is no current proof they extend lifespan.
  • GLP-1s are not currently approved for longevity but can be prescribed off-label, including for microdosing. Experts emphasize that these drugs should complement — not replace — foundational lifestyle habits like nutrition, exercise, sleep, and stress management.

Resources We Trust

EDITORIAL SOURCES
Everyday Health follows strict sourcing guidelines to ensure the accuracy of its content, outlined in our editorial policy. We use only trustworthy sources, including peer-reviewed studies, board-certified medical experts, patients with lived experience, and information from top institutions.
Resources
  1. Friedman JM. The Discovery and CDevelopment of GLP-1 Based Drugs That Have Revolutionized the Treatment of Obesity. PNAS. September 19, 2024.
  2. FDA Approves First Treatment to Reduce Risk of Serious Heart Problems Specifically in Adults with Obesity or Overweight. U.S. Food & Drug Administration. March 8, 2024.
  3. FDA Approves First Medication for Obstructive Sleep Apnea. U.S. Food & Drug Administration. December 20, 2024.
  4. FDA Approves Treatment for Serious Liver Disease Known as MASH. U.S. Food & Drug Administration. August 15, 2025.
  5. Peng W et al. Novel Insights into the Roles and Mechanisms of GLP-1 Receptor Agonists against Aging-Related Diseases. Aging and Disease. 2022.
  6. Oxidative Stress. Cleveland Clinic. February 29, 2024.
  7. Li XZ et al. From Biological Aging to Functional Decline: Insights Into Chronic Inflammation and Intrinsic Capacity. Ageing Research Reviews. January 2024.
  8. Heart Disease Remains Leading Cause of Death as Key Health Risk Factors Continue to Rise. American Heart Association. January 27, 2025.
  9. Deanfield J et al. Semaglutide and Cardiovascular Outcomes In Patients With Obesity and Prevalent Heart Failure: A Prespecified Analysis of the SELECT Trial. The Lancet. August 24, 2024.
  10. GLP-1 Receptor Agonists (GLP-1 RAs). National Kidney Foundation. September 16, 2024.
  11. Dai H et al. GLP-1 Receptor Agonists and Cancer Risk in Adults With Obesity. JAMA Oncology. August 21, 2025.
  12. Mitochondria and Health. National Institutes of Health. July 22, 2025.
  13. Wang W et al. Associations Of Semaglutide With First-Time Diagnosis Of Alzheimer’s Disease In Patients With Type 2 Diabetes: A Real-World Evidence Study. Alzheimer's & Dementia. October 24, 2024.
  14. Weight Benefits, Risks Carefully Before Taking Off-Label Medication. Mayo Clinic. February 3, 2023.
  15. FDA’s Concerns with Unapproved GLP-1 Drugs Used for Weight Loss. U.S. Food and Drug Administration. September 25, 2025.
  16. Should You Microdose GLP-1s? Cleveland Clinic. August 28, 2025.
  17. Onoviran OF et al. Effects of Glucagon-Like Peptide 1 Receptor Agonists on Comorbidities in Older Patients With Diabetes Mellitus. Therapeutic Advances in Chronic Disease. July 12, 2019.
  18. Age and Muscle Loss. Harvard Health Publishing. February 14, 2023.
  19. Sodhi M et al. Risk of Gastrointestinal Adverse Events Associated With Glucagon-Like Peptide-1 Receptor Agonists for Weight Loss. JAMA. October 5, 2023.
  20. Diabetes Drugs and Weight Loss. Mayo Clinic. November 14, 2024.
Meet Our Experts
See Our Editorial PolicyMeet Our Health Expert Network
Stephanie-Young-Moss-bio

Stephanie Young Moss, PharmD

Medical Reviewer

Stephanie Young Moss, PharmD, has worked in pharmacy, community outreach, regulatory compliance, managed care, and health economics and outcomes research. Dr. Young Moss is the owner of Integrative Pharmacy Outcomes and Consulting, which focuses on educating underserved communities on ways to reduce and prevent health disparities. She uses her platform to educate families on ways to decrease and eliminate health disparities by incorporating wellness and mental health techniques.

Young Moss is the creator of the websites DrStephanieYoMo.com and MenopauseInColor.com, providing practical health and wellness tips and resources for women experiencing perimenopause and menopause. She has over 100,000 people in her social media communities. She has also contributed to Pharmacy Times and shared her views on international and national podcasts and local television news.

She has served on various boards for organizations that focus on health equity, decreasing implicit bias, addressing social determinants of health, and empowering communities to advocate for their health. She has also been on the boards for the Minority Health Coalition of Marion County and Eskenazi Health Center, for which she was the clinical quality committee chair and board secretary and is currently the board treasurer. She is a board member for Community Action of Greater Indianapolis.

See full bio

Susan Jara

Author

Susan Jara is a health communications strategist and writer with more than 15 years of experience transforming complex medical information into clear, accurate, and engaging content for diverse audiences of patients and caregivers. She specializes in patient education, health literacy, and SEO-driven content strategy, with expertise across chronic disease, mental health, addiction, arthritis, autoimmune conditions, and wellness.

Susan holds a bachelor’s degree in journalism and media studies from New York University’s Gallatin School of Individualized Study. Her career includes leadership roles at the Global Healthy Living Foundation and Health Monitor Network, where she developed multichannel health content across web, email, podcasts, video, social media, and print. Susan's work reaches millions of readers each year, and she collaborates with leading healthcare providers, researchers, advocacy groups, and industry partners to create resources that reach millions of readers each year.

See full bio
See Our Editorial PolicyMeet Our Health Expert Network